Lancet (London, England)

Heart health results with survodutide in adults with obesity and higher heart risk

Updated

Abstract

Survodutide improved markers of cardiometabolic health in people with obesity.

  • Survodutide acts as a dual agonist for glucagon and GLP-1 receptors.
  • Improvements were noted in various markers associated with cardiometabolic health.
  • The cardiovascular safety of this new class of medication is still uncertain.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free